Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Cipla
US Army
Novartis
Dow
Citi
Fish and Richardson
Colorcon
Argus Health
Accenture

Generated: August 16, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Anti-cancer compounds
Abstract: This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
Inventor(s): Aylward; James Harrison (St. Lucia, AU)
Assignee: Peplin Research Pty. Ltd. (Fortitude Valley, AU)
Application Number:10/896,811
Patent Claims: 1. A method for inhibiting proliferative activity of neoplastic cells in a subject, said method comprising administering to a subject in need thereof a therapeutically effective amount of an isolated compound, said compound being an angeloyl-substituted ingenane.

2. The method of claim 1, wherein the compound is selected from the group consisting of an angeloyl-substituted ingenane with an acylated substitution on or at the C-20 position.

3. The method of claim 1, wherein the compound is 20-O-acetyl-ingenol-3-angelate.

4. The method of claim 1 wherein the neoplastic cells are present in a subject with cancer or a tumor.

5. The method of claim 4 wherein the cancer or tumor is selected from the group consisting of skin cancer, malignant melanoma, merkel cell carcinoma, squamous cell carcinoma, basal cell carcinoma and solar keratosis.

6. The method of claim 4 wherein the cancer or tumor is selected from the group consisting of a solid tumor, lung cancer, colon cancer, prostate cancer, cervical cancer and breast cancer.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Fuji
Express Scripts
Novartis
Moodys
Daiichi Sankyo
Teva
Colorcon
Cipla
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot